MX2016009217A - Inmunoterapia basada en liposomas. - Google Patents
Inmunoterapia basada en liposomas.Info
- Publication number
- MX2016009217A MX2016009217A MX2016009217A MX2016009217A MX2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A
- Authority
- MX
- Mexico
- Prior art keywords
- liposome
- pharmaceutical
- veterinary compositions
- provides
- defined above
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Abstract
La presente invención proporciona un liposoma que encapsula un autoantígeno, en el que el liposoma tiene un tamaño comprendido entre 500 y 15000 nm y la membrana del liposoma comprende fosfatidilserina (PS) en una cantidad comprendida entre el 10 y el 40% en peso con respecto a la composición liposómica total de membrana. También se proporcionan composiciones farmacéuticas o veterinarias que comprenden una cantidad terapéuticamente eficaz de dicho liposoma. Además, la invención proporciona liposomas y composiciones farmacéuticas o veterinarias como se han definido anteriormente para uso como un medicamento, particularmente para el tratamiento de enfermedades autoinmunes. Finalmente la presente invención proporciona liposoma y composiciones farmacéuticas o veterinarias como se ha definido anteriormente para uso en la restauración de autotolerancia en un paciente que padece una enfermdad autoinmune.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14151629 | 2014-01-17 | ||
PCT/EP2015/050747 WO2015107140A1 (en) | 2014-01-17 | 2015-01-16 | Liposome-based immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009217A true MX2016009217A (es) | 2017-05-12 |
Family
ID=49949574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009217A MX2016009217A (es) | 2014-01-17 | 2015-01-16 | Inmunoterapia basada en liposomas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160338953A1 (es) |
EP (1) | EP3094345B1 (es) |
JP (2) | JP6546195B2 (es) |
CN (1) | CN106061502B (es) |
AU (1) | AU2015206016B2 (es) |
BR (1) | BR112016016356B1 (es) |
CA (1) | CA2939435C (es) |
ES (1) | ES2672247T3 (es) |
MX (1) | MX2016009217A (es) |
PL (1) | PL3094345T3 (es) |
TR (1) | TR201807778T4 (es) |
WO (1) | WO2015107140A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201807778T4 (tr) * | 2014-01-17 | 2018-06-21 | Fundacio Inst Catala De Nanociencia I Nanotecnologia | Lipozom bazlı immünoterapi. |
EP2918262B1 (en) * | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. | シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用 |
US11315437B2 (en) * | 2017-02-24 | 2022-04-26 | Rene Ebner-Todd | Nutrition management and kitchen appliance |
US20220409702A1 (en) * | 2019-11-22 | 2022-12-29 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
WO1998010748A1 (en) * | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
CA2319928A1 (en) * | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
JP4889485B2 (ja) * | 2004-06-11 | 2012-03-07 | 独立行政法人理化学研究所 | 調節性細胞リガンドをリポソームに含有させてなる医薬 |
CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
WO2007014754A1 (en) * | 2005-08-02 | 2007-02-08 | I.D.M. Immuno-Designed Molecules | Process for the preparation of liposomal formulations |
JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
US20110111395A1 (en) * | 2008-02-14 | 2011-05-12 | Jean-Marie Saint-Remy | Cd4+cells with cytolytic properties |
CN101502649B (zh) * | 2008-06-23 | 2011-11-30 | 深圳职业技术学院 | 一种脂质体流感疫苗 |
WO2011005850A1 (en) * | 2009-07-07 | 2011-01-13 | The Research Foundation Of State University Of New York | Lipidic compositions for induction of immune tolerance |
ES2634669T3 (es) * | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
EA027410B1 (ru) * | 2011-04-29 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов |
WO2013184976A2 (en) * | 2012-06-06 | 2013-12-12 | Northwestern University | Compositions and methods for antigen-specific tolerance |
TR201807778T4 (tr) * | 2014-01-17 | 2018-06-21 | Fundacio Inst Catala De Nanociencia I Nanotecnologia | Lipozom bazlı immünoterapi. |
-
2015
- 2015-01-16 TR TR2018/07778T patent/TR201807778T4/tr unknown
- 2015-01-16 CN CN201580007978.3A patent/CN106061502B/zh active Active
- 2015-01-16 EP EP15700478.9A patent/EP3094345B1/en active Active
- 2015-01-16 MX MX2016009217A patent/MX2016009217A/es active IP Right Grant
- 2015-01-16 US US15/111,466 patent/US20160338953A1/en active Pending
- 2015-01-16 CA CA2939435A patent/CA2939435C/en active Active
- 2015-01-16 WO PCT/EP2015/050747 patent/WO2015107140A1/en active Application Filing
- 2015-01-16 BR BR112016016356-7A patent/BR112016016356B1/pt active IP Right Grant
- 2015-01-16 ES ES15700478.9T patent/ES2672247T3/es active Active
- 2015-01-16 PL PL15700478T patent/PL3094345T3/pl unknown
- 2015-01-16 AU AU2015206016A patent/AU2015206016B2/en active Active
- 2015-01-16 JP JP2016564400A patent/JP6546195B2/ja active Active
-
2019
- 2019-06-20 JP JP2019114294A patent/JP2019196363A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112016016356A2 (pt) | 2017-10-03 |
PL3094345T3 (pl) | 2018-11-30 |
CN106061502A (zh) | 2016-10-26 |
EP3094345B1 (en) | 2018-03-14 |
ES2672247T3 (es) | 2018-06-13 |
CN106061502B (zh) | 2021-04-13 |
CA2939435C (en) | 2023-09-19 |
EP3094345A1 (en) | 2016-11-23 |
BR112016016356B1 (pt) | 2023-12-26 |
CA2939435A1 (en) | 2015-07-23 |
WO2015107140A1 (en) | 2015-07-23 |
TR201807778T4 (tr) | 2018-06-21 |
JP2019196363A (ja) | 2019-11-14 |
JP2017507171A (ja) | 2017-03-16 |
JP6546195B2 (ja) | 2019-07-17 |
AU2015206016B2 (en) | 2020-07-23 |
US20160338953A1 (en) | 2016-11-24 |
AU2015206016A1 (en) | 2016-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
AU2017265937A1 (en) | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
IN2015DN00376A (es) | ||
PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
TN2012000611A1 (en) | Formulations of rifaximin and uses thereof | |
MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
EA201791738A1 (ru) | Пролипосомальные композиции тестостерона | |
JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
MX2016009217A (es) | Inmunoterapia basada en liposomas. | |
MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
WO2015033302A3 (en) | Fulvestrant compositions | |
MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
TN2012000488A1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |